Skip to main content
. 2021 Oct 1;28(6):925–932. doi: 10.1177/13524585211047223

Figure 1.

Figure 1.

Adjudicated attacks in AQP4–IgG–seropositive participants receiving inebilizumab for ⩾4 years. (a) Timeline of adjudicated attacks for AQP4–IgG–seropositive participants with ⩾4 years of inebilizumab treatment. (b) Kaplan–Meier plot of attack-free probability after initiation of inebilizumab.

AQP4: aquaporin-4; Ig: immunoglobulin; NMOSD: neuromyelitis optica spectrum disorder; OLE: open-label extension; RCP: randomized controlled period.